WebTurnstone Biologics has raised a total of $132.7M in funding over 5 rounds. Their latest funding was raised on Jul 14, 2024 from a Series D round. Turnstone Biologics is funded by 20 investors. Brace Pharma and Ridgeback Capital are the most recent investors. Turnstone Biologics has a post-money valuation in the range of $500M to $1B as of Jul ... Web19 apr 2024 · Built on a proprietary vaccinia virus platform, Turnstone is evaluating its viral immunotherapy program, RIVAL-01/TAK-605, in an ongoing Phase 1/2a trial as part of a …
Series D - Turnstone Biologics - 2024-07-14 - CrunchBase
Web21 lug 2024 · Leading U.S. life sciences investors chip in US$80-million to help fund Turnstone Biologics’ second ... Turnstone can receive another US$900-million in payments from Takeda if the drug ... Web19 dic 2024 · Takeda has partnered with Turnstone to discover and develop immunotherapies using the biotech’s engineered vaccinia virus platform in a deal that … gewicht dacia sandero stepway
Turnstone Biologics Announces First Patients Enrolled in Phase 1/2 ...
Web29 nov 2024 · NEW YORK--(BUSINESS WIRE)-- Turnstone Biologics Corp., a clinical-stage biotechnology company pioneering the development of cancer immunotherapies, today announced that it has entered into a strategic multi-year research collaboration with Moffitt Cancer Center (“Moffitt”) for pre-clinical development of investigational tumor … Web29 nov 2024 · The Company has an ongoing Phase 1/2a trial in solid tumors (RAPTOR) for its leading oncolytic virus candidate, RIVAL-01/TAK-605, which is being developed under … Web19 dic 2024 · NEW YORK, NY, USA I December 19, 2024 I Turnstone Biologics, a biotechnology company pioneering the development of engineered viral … christopher\u0027s beaverdale iowa